

**Call title: HEALTH-2013-INNOVATION**

**Call identifier:** FP7-HEALTH-2013-INNOVATION-1

**Proposal submission and evaluation:** two-stage procedure.

**Date of publication:** 10 July 2012

**Deadline for stage 1 proposals:** 02 October 2012 at 17:00:00 (Brussels local time)<sup>1</sup>

**Indicative budget:** EUR 679.3 million from the 2013 budget<sup>2</sup>

*The budget for this call is indicative. The final budget awarded to actions implemented through calls for proposals may vary:*

*The total budget of the call may vary by up to 10% of the total value of the indicated budget for each call; and*

*Any repartition of the call budget may also vary by up to 10% of the total value of the indicated budget for the call.*

**For description of the topics of the calls, please refer to section II 'Content of calls'**

**Table 1: Indicative budget lines**

ACTIVITY/AREA	Indicative budget (EUR million)
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH	
1.2 DETECTION, DIAGNOSIS AND MONITORING	36
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES	60
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS	36
2. TRANSLATING RESEARCH FOR HUMAN HEALTH	
2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY	
2.1.1 LARGE-SCALE DATA GATHERING	
2.1.1-1 Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes	36
2.1.1-2 High impact research initiative on metagenomics for personalised medicine approaches	30
2.2 RESEARCH ON THE BRAIN AND BRAIN-RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING	
2.2.1 RESEARCH ON THE BRAIN AND BRAIN-RELATED DISEASES	
2.2.1-1 Traumatic brain injury	30
2.2.1-2, -3, -4, -5 Mental health, neurology and pain	96

<sup>1</sup> The Director-General responsible for this call may delay this deadline by up to two months.

<sup>2</sup> Under the condition that the draft budget for 2013 is adopted without modifications by the budgetary authority.

FP7 Cooperation Work Programme: Health 2013  
Call: FP7-HEALTH-2013-INNOVATION-1

2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH	
2.3.0 CROSS-CUTTING PRIORITIES	42
2.3.1 ANTI-MICROBIAL DRUG RESISTANCE	24
2.3.3 EMERGING EPIDEMICS	24
2.3.4 NEGLECTED DISEASES	33
2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	
2.4.1 CANCER	72
2.4.2 CARDIOVASCULAR DISEASES	54
3 OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS	
3.1 TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIESHEALTH CARE SYSTEMS	30
3.3 HEALTH PROMOTION AND PREVENTION	24
4 OTHER ACTIONS ACROSS THE HEALTH THEME	
4.1 COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	10.3
4.2 RESPONDING TO EU POLICY NEEDS	42

**Table 2: Topics called:**

Activity/Area	Topics called	Funding Schemes and additional eligibility criteria
1 BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH		
1.2 DETECTION, DIAGNOSIS & MONITORING		
1.2	HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases.  <i>One or more proposals may be selected.</i>	<i>SME-targeted Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES		
1.3	HEALTH.2013.1.3-1: Modelling toxic responses in case studies for predictive human safety assessment.  <i>Only one proposal may be selected.</i>	<i>Collaborative Project (large-scale integrating research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 12 000 000. The estimated EU contribution going to industry including SME(s) shall be 15% or more of the total estimated EU contribution for the project as a whole. The SME status and the</i>

FP7 Cooperation Work Programme: Health 2013  
Call: FP7-HEALTH-2013-INNOVATION-1

		<i>financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
1.3	HEALTH.2013.1.3-2: Innovative approaches to address adverse immune reactions to biomedical devices, implants and transplant tissues.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to industry including SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
1.3	HEALTH.2013.1.3-3: Safety and efficacy of therapeutic vaccines.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to industry including SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
1.3	HEALTH.2013.1.3-4: Development of alternative <i>in vitro</i> , analytical, immunochemical, and other test methods for quality control of vaccines.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 3 000 000. The estimated EU contribution going to industry including SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS		
1.4	HEALTH.2013.1.4-1. Controlling differentiation and proliferation in human stem cells intended for therapeutic use.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to SME(s) shall be 15% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
2 TRANSLATING RESEARCH FOR HUMAN HEALTH		
2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY		
2.1.1 Large-scale data gathering		
2.1.1	HEALTH.2013.2.1.1-1: Functional validation in animal and cellular models of genetic determinants of diseases and	<i>SME-targeted Collaborative Project (large-scale integrating research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 12 000 000. The estimated EU</i>

FP7 Cooperation Work Programme: Health 2013  
Call: FP7-HEALTH-2013-INNOVATION-1

	<p>ageing processes.</p> <p><i>One or more proposals may be selected.</i></p>	<p><i>contribution going to SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i></p>
2.1.1	<p>HEALTH.2013.2.1.1-2: High impact research initiative on metagenomics for personalised medicine approaches.</p> <p><i>Only one proposal may be selected.</i></p>	<p><i>Collaborative Project (large-scale integrating research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 30 000 000. The estimated EU contribution going to industry including SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i></p>
2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING		
2.2.1 Research on the brain and brain-related diseases		
2.2.1	<p>HEALTH.2013.2.2.1-1: Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI).</p> <p><i>One or more proposals may be selected.</i></p>	<p><i>Collaborative Project (large-scale integrating research project). Additional eligibility criterion: The requested contribution per project shall not exceed EUR 30 000 000.</i></p>
2.2.1	<p>HEALTH.2013.2.2.1-2: Development of effective imaging tools for diagnosis, monitoring and management of mental disorders<sup>3</sup>.</p> <p><i>One or more proposals may be selected.</i></p>	<p><i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to industry including SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i></p>
2.2.1	<p>HEALTH.2013.2.2.1-3: Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment.</p> <p><i>One or more proposals may be selected.</i></p>	<p><i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to SME(s) shall be 15% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i></p>
2.2.1	<p>HEALTH.2013.2.2.1-4: Patho-physiology and therapy of epilepsy and epileptiform disorders.</p> <p><i>One or more proposals may be selected.</i></p>	<p><i>Collaborative Project (large-scale integrating research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 12 000 000. The estimated EU contribution going to SME(s) shall be 15% or more of the total estimated EU contribution for the project as a</i></p>

<sup>3</sup> As defined in the Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> edition.

FP7 Cooperation Work Programme: Health 2013  
Call: FP7-HEALTH-2013-INNOVATION-1

		<i>whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement a whole.</i>
2.2.1	HEALTH.2013.2.2.1-5: Understanding and controlling pain.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000.</i>
2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH		
2.3.0 Cross-cutting priorities		
2.3.0	HEALTH.2013.2.3.0-1: Innovation in vaccines.  <i>One or more proposals may be selected.</i>	<i>SME-targeted Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
2.3.1 Anti-microbial drug resistance		
2.3.1	HEALTH.2013.2.3.1-2: Stratified approaches to antibacterial and/or antifungal treatment.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000.</i>
2.3.3 Potentially new and re-emerging epidemics		
2.3.3	HEALTH.2013.2.3.3-1: Clinical management of patients in severe epidemics.  <i>Only one proposal may be selected.</i>	<i>Collaborative Project (large-scale integrating research project). Only up to one proposal may be selected. Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 24 000 000.</i>
2.3.4 Neglected infectious diseases		
2.3.4	HEALTH.2013.2.3.4-1: Neglected infectious diseases of Central and Eastern Europe.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 3 000 000.</i>
2.3.4	HEALTH.2013.2.3.4-2: Drug development for neglected parasitic diseases.  <i>One or more proposals may be selected.</i>	<i>SME-targeted Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to SME(s) shall be 15% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>

FP7 Cooperation Work Programme: Health 2013  
Call: FP7-HEALTH-2013-INNOVATION-1

2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES		
2.4.1 Cancer		
2.4.1	HEALTH.2013.2.4.1-1: Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000.</i>
2.4.1	HEALTH.2013.2.4.1-2: Strengthening the cancer patient's immune system.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to industry including SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
2.4.1	HEALTH.2013.2.4.1-3: Investigator-driven supportive and palliative care clinical trials and observational studies.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000.</i>
2.4.2 Cardiovascular diseases		
2.4.2	HEALTH.2013.2.4.2-1: Discovery research to reveal novel targets for cardiovascular disease treatment.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
2.4.2	HEALTH.2013.2.4.2-2: Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000.</i>
2.4.2	HEALTH.2013.2.4.2-3: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 3 000 000.</i>
3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS		
3.2 TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER		

FP7 Cooperation Work Programme: Health 2013  
Call: FP7-HEALTH-2013-INNOVATION-1

USE OF MEDICINES, APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES.		
3.1	HEALTH.2013.3.1-1: Comparative Effectiveness Research (CER) in health systems and health services interventions.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000.</i>
3.3 HEALTH PROMOTION AND PREVENTION		
3.3	HEALTH.2013.3.3-1: Social innovation <sup>4</sup> for health promotion.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to SME(s) shall be 15% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
4 OTHER ACTIONS ACROSS THE HEALTH THEME		
4.1 COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME		
4.1	HEALTH.2013.4.1-1: Supporting industrial participation in EU-funded research in the Health sector.  <i>Only up to one proposal may be selected.</i>	<i>Coordination and Support Action (coordinating action). Additional eligibility criterion: Requested EU contribution per action: Maximum EUR 2 500 000.</i>
4.1	HEALTH.2013.4.1-2: Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation.  <i>One or more proposals may be selected.</i>	<i>Coordination and Support Action (supporting action). Additional eligibility criterion: Requested EU contribution per action: Maximum EUR 500 000.</i>
4.1	HEALTH.2013.4.1-3: Support for Presidency events: Organisation of supporting actions and events associated to the Presidency of the European Union.  <i>One or more proposals may be</i>	<i>Coordination and Support Action (supporting action). Additional eligibility criterion: Requested EU contribution per action: Maximum EUR 100 000.</i>

<sup>4</sup> Social innovations are new ideas (products, services and models) that simultaneously meet social needs (more effectively than alternatives) and create new social relationships or collaborations. In other words they are innovations that are not only good for society but also enhance society's capacity to act.  
[http://ec.europa.eu/enterprise/policies/innovation/policy/social-innovation/index\\_en.htm](http://ec.europa.eu/enterprise/policies/innovation/policy/social-innovation/index_en.htm)

It covers wide fields which range from new models of child care to web-based social networks, from the provision of domestic healthcare to new ways of encouraging people to exchange cars for bicycles in cities, and the development of global fair-trade chains. It may be a new product, service, initiative, organisational model or approach to the delivery of public services.

FP7 Cooperation Work Programme: Health 2013  
Call: FP7-HEALTH-2013-INNOVATION-1

	<i>selected.</i>	
4.1	HEALTH.2013.4.1-4: Preparing the future for health research and innovation.  <i>One or more proposals may be selected.</i>	<i>Coordination and Support Action (supporting action). Additional eligibility criterion: Requested EU contribution per action: Maximum EUR 500 000.</i>
4.1	HEALTH.2013.4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations.  <i>Only up to one proposal may be selected.</i>	<i>Coordination and Support Action (coordinating action). Additional eligibility criterion: Requested EU contribution per action: Maximum EUR 2 000 000.</i>
4.1	HEALTH.2013.4.1-6: Mapping chronic non-communicable diseases research activities.  <i>Only up to one proposal may be selected.</i>	<i>Coordination and Support Action (coordinating action). Additional eligibility criterion: Requested EU contribution per action: Maximum EUR 2 000 000.</i>
4.1		
4.2 RESPONDING TO EU POLICY NEEDS		
4.2	HEALTH.2013.4.2-1: Investigator-driven clinical trials for off-patent medicines using innovative, age-appropriate formulations and/or delivery systems.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small or medium-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 6 000 000. The estimated EU contribution going to industry including SME(s) shall be 30% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
4.2	HEALTH.2013.4.2-2: Adverse drug reaction research.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 3 000 000. The estimated EU contribution going to SME(s) shall be 15% or more of the total estimated EU contribution for the project as a whole. The SME status and the financial viability will be assessed at the end of the negotiation, before signature of the grant agreement.</i>
4.2	HEALTH.2013.4.2-3: New methodologies for clinical trials for small population groups.  <i>One or more proposals may be selected.</i>	<i>Collaborative Project (small-scale focused research project). Additional eligibility criterion: Requested EU contribution per project: Maximum EUR 3 000 000.</i>

### Conditions for FP7-HEALTH-2013-INNOVATION-1

It is important to note that the basic conditions for eligibility shall be met, such as the minimum number of participants (in most cases 3 from different MS or AC, except for supporting actions) or the budget ceiling for the maximum requested EU contribution.



However **there is no obligation to go beyond the minimum number of participants unless additional partners are needed to achieve the objectives of the project.** The **duration of the project** shall be in line with the realistic planning of the project. The size of the **EU contribution** to the budget shall also be in line with the needs of the consortia, within the maximum EU contribution, but does not necessarily need to be the maximum.

The quality, feasibility, implementation and impact of the proposed work as well as the match between the expertise of the consortium and the project goals are subject to the evaluation carried out by independent experts.

In recognition of the opening of NIH<sup>5</sup> programmes to European researchers, participants established in the *United States of America* are entitled to participate and to receive funding<sup>6</sup> in all topics under this call.

Eligibility criteria for each proposal are checked by Commission staff before the evaluation begins. Proposals which do not fulfil any of the criteria will not be evaluated.

**Eligibility criteria (stage 1 and stage 2):**

The general eligibility criteria are set out in Annex 2 to this work programme, and in the guide for applicants for each funding scheme. Please note that the completeness criterion also includes that part B of the proposal shall be readable, accessible and printable.

**Table 3:** Standard minimum number of participating legal entities for all funding schemes used in the call, in line with the Rules for Participation and in the below format, unless otherwise specified in section II of the work programme.

<b>Funding scheme</b>	<b>Minimum conditions<sup>7</sup></b>
Collaborative Project	At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC
Coordination and Support Action (coordinating action)	At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC
Coordination and Support Action (supporting action)	At least 1 legal entity

The eligibility criteria will apply to both first and second stage proposals. At stage 1, only information provided in part A of the proposal will be used to determine whether the proposal is eligible with respect to overall budget threshold (budget ceilings for requested EU

---

<sup>5</sup> National Institutes of Health of the US Department of Health and Human Services

<sup>6</sup> In accordance with Article 29 of Regulation (EC) No 1906/2006 of 18 December 2006 laying down the rules for the participation of undertakings, research centres and universities in actions under the Seventh Framework Programme and for the dissemination of research results (2007-2013).

<sup>7</sup> These can differ for specific topics, please consult always the topic description in section II

contribution per project), while part B will be used to check the number of eligible participants. At stage 2, part A will be used alone to determine these eligibility criteria.

**The following additional eligibility criteria apply in this call:**

- **At stage 1 and stage 2**, it is important to note that the upper limits (ceilings) for the requested EU contribution given per topic in section II of this work programme will be applied as an additional eligibility criterion and proposals, which do not respect these limits, will be considered as ineligible.
- **At stage 2**, for topics requiring a certain percentage of EU funding going to SMEs or industry, the following additional eligibility criterion will be verified: Projects will only be selected for funding on the condition that the estimated EU contribution going to SME(s) or industry is at the threshold (or more for the project as a whole) as set out with the respective topic description in section II. *The SME status and the financial viability will be finally assessed during the negotiation, before signature of the grant agreement. Proposals not fulfilling this criterion will not be funded.*

**Evaluation procedure:**

- The evaluation criteria and scoring scheme are set out in annex 2 to the work programme and the guide for applicants.
  - Proposal page limits: Applicants will ensure that proposals conform to the page limits and layout given in the Guide for Applicants, and in the proposal part B template available through the electronic Submission Services of the Commission. No annexes are allowed to the proposal.
- The Commission will instruct the experts to disregard any pages exceeding these limits.
- The minimum font size allowed is 11 points. The page size is A4, and all margins (top, bottom, and left, right) should be at least 15 mm (not including any footers or headers).
- A two-stage submission and evaluation procedure will be used.
- Experts will carry out the individual evaluation of proposals remotely.
- **For the evaluation of topics "HEALTH.2013.2.1.1-2: High impact research initiative on metagenomics for personalised medicine approaches", "HEALTH.2013.2.2.1-1: Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI)" and "HEALTH.2013.2.3.3-1: Clinical management of patients in severe epidemics", the Commission will organise hearings<sup>8</sup> at stage 2 with applicants as part of the panel deliberations for all proposals above threshold.**

---

<sup>8</sup> Details about the procedure are provided in an explanatory memorandum on the call web page.

**Additional information regarding evaluation criteria and procedures:**

- *For proposals failing to achieve a threshold for a criterion, the evaluation of the proposal will be stopped at the first criterion failing a threshold. Therefore for such proposals the ESR (evaluation summary report) will not contain marks and comments for the remaining criteria. Successful proposals will need to pass the minimum thresholds.*
- *In line with the objectives of each topic, additional evaluation criteria may be indicated in the work programme under the respective topic in section II.*
- *The following aspects will be considered for SME-targeted Collaborative Projects under the evaluation criterion relating to 'implementation':*
  - ➔ *Proposals are expected to have a substantial involvement of SMEs. As an indication of the expected level of involvement, evaluators should note that only proposals which fulfil the conditions as set out in the topic for the percentage of the estimated EU contribution going to SMEs will be eventually selected. The SME status and the financial viability will be checked definitively at the end of any negotiation.*
  - ➔ *The leading role of SMEs with R&D capacities: the coordinator does not need to be an SME, but the participating SMEs will need to have a decision making power in the project management, and the output should be for the benefit of the participating SMEs and the targeted SME-dominated industrial communities.*
- **Proposal ranking:** *The series of priority lists will be prepared by the panels of external experts, per indicative budget line as set out in table 1 of this call fiche. The aspects taken into account for establishing a priority order for ranking of proposals are set out in annex 2 of the work programme.*

**Stage 1 proposals**

- *Stage 1 proposals shall be submitted by the deadline mentioned above.*
- *Stage 1 proposals shall follow the instructions set out in the guide for applicants and in the proposal part B template available through electronic Submission Services of the Commission. Proposals should focus on the overall scientific and technological content and on clear identification of the milestones and deliverables to be reached (intended results), the intended use of the results and the expected impact (scientific, economic, social, environmental, etc. and as set out in section II under each topic) in a **maximum of 6 pages (excluding the cover page and the required tables)**. **No annexes are allowed to the proposal i.e. applicants have to strictly follow the template for part B and may not create more sections or annexes within this document.** The maximum page limits of each section shall be respected. The Commission will instruct the independent external experts (evaluators of proposals) to disregard any pages in excess of these limits. A minimum font size of 11 is required.*
- *Stage 1 proposals will be individually evaluated remotely by independent external experts and discussed in consensus meetings.*
- *Stage 1 proposals will be evaluated on the basis of the following two criteria: **Scientific/technological quality and Impact**. For each criterion, marks from 0 to 5 will be given, with the possibility of half-point scores. For proposals failing to achieve a*

*threshold for a criterion, the evaluation of the proposal will be stopped at the first criterion failing a threshold. Therefore for such proposals the ESR (evaluation summary report) will not contain marks and comments for the remaining criteria. Proposals will need to pass the minimum thresholds as follows:*

**Table 4: Thresholds for evaluation criteria for first stage**

<b>Criterion</b>	<b>Minimum threshold</b>
<b>S/T quality</b>	<b>4/5</b>
<b>Impact</b>	<b>3/5</b>
<b>Overall threshold</b>	<b>8/10</b>

- *All Proposals passing all thresholds will be retained at stage 1. Successful proposals will not receive an ESR<sup>9</sup>.*
- *Coordinators of proposals retained at stage 1 (proposals passing the evaluation thresholds) will be invited to submit a complete proposal (stage 2 proposal) that will then be evaluated against the entire set of evaluation criteria. In line with the objectives of each topic, additional eligibility criteria may be indicated in section II of the work programme.*

### **Stage 2 proposals**

- *The deadline for submission for stage 2 proposals will be specified in the invitation to submit. The **indicative deadline** for stage 2 proposals is in the beginning of February 2013.*
- *Stage 2 proposals shall follow the instructions set out in the guide for applicants and in the proposal part B template available through electronic Submission Services of the Commission. **No annexes are allowed to the proposal i.e. applicants have to strictly follow the template for part B and may not create more sections or annexes within this document.** The maximum page limits of each section shall be respected. The Commission will instruct the independent external experts (evaluators of proposals) to disregard any pages in excess of these limits. A minimum font size of 11 is required.*
- *Stage 2 proposals are evaluated on the basis of the following three criteria: **Scientific/technological quality, Implementation and Impact.***
- *For each criterion, marks from 0 to 5 will be given, with the possibility of half-point scores. For proposals failing to achieve a threshold for a criterion, the evaluation of the*

---

<sup>9</sup> See annex C of the "Rules for submission of proposals, and the related evaluation, selection and award procedures"; COMMISSION DECISION C(2011)1132 of 28 February 2011.

*proposal will be stopped at the first criterion failing a threshold. Therefore for such proposals the ESR (evaluation summary report) will not contain marks and comments for the remaining criteria. Proposals will need to pass the minimum thresholds as follows:*

**Table 5: Thresholds for evaluation criteria for second stage**

<b>Criterion</b>	<b>Minimum threshold</b>
<b>S/T quality</b>	<b>4/5</b>
<b>Implementation</b>	<b>3/5</b>
<b>Impact</b>	<b>3/5</b>
<b>Overall threshold</b>	<b>12/15</b>

- *In line with the objectives of each topic, additional evaluation criteria may be indicated in the work programme under the respective topic in section II.*
- *The following aspects will be considered for SME-targeted Collaborative Projects under the evaluation criterion relating to 'implementation':*

*Proposals are expected to have a substantial involvement of SMEs. As an indication of the expected level of involvement, applicants and evaluators should note that only proposals which fulfil the conditions as set out in the topic for the percentage of the estimated EU contribution going to SMEs will be eventually selected.*

*The leading role of SMEs with R&D capacities: the coordinator does not need to be an SME, but the participating SMEs should have a decision making power in the project management, and the output should be for the benefit of the participating SMEs and the targeted SME-dominated industrial communities.*

- *The SME and/or industrial status of participants and their financial viability will be checked definitively at the end of any negotiation of any kind of collaborative project requiring a certain SME and/or industrial participation.*

**Proposal ranking at stage 2:**

- *There will be differing numbers of proposals short-listed according to the topic description in section II and the available budget.*
- *However, there may be topics for which no proposals are of sufficient quality to be selected for funding, as there will be competition within topics and between topics on the basis of the quality of the proposals.*
- *The Commission ranked lists of proposals to be retained for negotiation will be based on the priority list established by the panel of independent external experts at stage 2 taking into account the budget available for each budget line (as indicated in this call for proposals). For each budget line, a number of proposals below the indicative budget cut-off line on the Commission ranked list may be kept on a reserve list to allow for eventualities such as the failure of negotiations on grant agreements, the withdrawal of*

*proposals, budget savings agreed during negotiation, or the availability of additional budget from other sources.*

**Indicative timetable for Stage 1 and 2:** The stage 1 evaluation should be finalised by mid December 2012. The deadline for stage 2 proposals will be in the beginning of February 2013. The evaluation of the stage 2 is expected to take place in March 2013. Overall evaluation results are estimated to be available within 3 months after the closure date for stage 2 proposals. It is expected that grant agreement negotiations for short-listed proposals begin in May 2013.

**Consortium agreements:** Participants in collaborative are required to conclude a consortium agreement. For **coordination and support actions** a consortium agreement is not mandatory.

**Forms of grant and maximum reimbursement rates** for projects funded through the Cooperation work programme are given in Annex 3.

**Flat rates to cover subsistence costs:** In accordance with Annex 3 to this work programme, this call provides for the possibility to use flat rates to cover subsistence costs incurred by beneficiaries during travel carried out within grants for indirect actions. For further information, see the relevant Guides for Applicants for this call. The applicable flat rates are available on the Participant Portal at: [https://ec.europa.eu/research/participants/portal/page/fp7\\_documents](https://ec.europa.eu/research/participants/portal/page/fp7_documents) under 'Guidance documents for FP7/Financial issues/Flat rates for daily allowances'.

**Dissemination:** Grant agreements of projects financed under this call for proposals will include the special clause 39 on the "Open Access Pilot in FP7". Under this clause, beneficiaries are required to make their best efforts to ensure free access to peer-reviewed articles resulting from projects via an institutional or subject-based repository.